MCW Cancer Center
The Medical College of Wisconsin Cancer Center is devoted to translating research into patient care. The MCW Cancer Center is an integrated partnership of cancer research scientists, physicians and clinical trial investigators and staff from the Medical College of Wisconsin, Froedtert Hospital, Children's Hospital of Wisconsin and Zablocki VA Medical Center, and the BloodCenter of Wisconsin. The Cancer Center, as part of MCW, is the only Academic cancer center in Southeastern Wisconsin. Learn More >>
Director's Update for November 22, 2016
Download the Director’s Update newsletter for November 22, 2016 here. Over the next 18 months, you’ll be hearing from us often as we track our progress, recognize accomplishments and milestones and provide updates on CCSG submission. We’ve also asked some of the most successful cancer center leaders from around the country to help guide us. You’ll be hearing from them about the game-changers, challenges and triumphs that led other centers to NCI Designation. If you go to page 12 of the newsletter, you will see an interview with Nathan Vanderford, PhD, from the Markey Cancer Center at the University of Kentucky. Dr. Vanderford is the assistant director of research at Markey and provided valuable insight about their membership and program process and keys to a successful designation submission.
If you have any questions, or ideas for upcoming issues of the Director’s Update. Please feel free to contact Dr. You, Marilyn Larson or Anne Mathias.
Dr. Joan Neuner Receives $2.33M NIH Grant to Study Breast Cancer Disparities
Joan Neuner, MD, MPH, the co-leader of the MCW Cancer Center Cancer Control and Outcomes program, was recently awarded a new R01 from the National Institute on Minority Health and Health Disparities (NIMHD) to study “Socioeconomic Disparities in Adherence to Oral Hormonal Therapy for Breast Cancer.” The research is based on her 2015 Journal of the National Cancer Institute (JNCI) paper which showed trends toward high rates of nonadherence in using Aromatase inhibitors were reversed with either copayment elimination or low-cost generics.
Dr. Neuner’s work is among the first to show the impact of high cost brand-name drugs on patient discontinuation of medications and that cost reductions associated with generic approval reversed this. She also found that very poor patients with low-income subsidies (LIS) that protected them from high out-of-pocket costs had high adherence to both brand-name and generic medications.
“Joan’s innovative ideas and research on breast cancer disparities is exactly the type of work we need as we prepare to submit for NCI Designation.” Said Ming You, MD, PhD, Director of the MCW Cancer Center. “This work not only puts us on the map nationally; it will have a direct influence on underserved populations in Southeastern Wisconsin.”
Cancer Clinical Trials Portal
This portal is directly linked to our Clinical Trials Management System and therefore, uses live real-time data, providing patients and referring physicians with the most up-to-date information on over 130 cancer clinical trials available throughout the Froedtert & the Medical College Cancer Network, MCW and our affiliates. This patient-friendly portal allows users to browse trials by disease type, conduct keyword searches, or conduct advanced searches by disease type or study location. There is also a specific area highlighting early-phase trials.
Read more about the MCW Cancer Center Clinical Trials Office
Please wait while we gather your results.